ADME/Tox Reagents for Research | Xenobiotic Metabolism Research Tools | Corning

We use cookies to ensure the best experience on our website.
View Cookie Policy
Accept Cookie Policy
Change My Settings
Required for the site to function.
Augment your site experience.
Lets Corning work with partners to enable social features and marketing messages.

Helping you make informed decisions in a continually changing environment.


A History of Advancing Drug Discovery Research

A History of Advancing Drug Discovery Research

Founded in 1983, the Gentest brand initially focused on the use of cultured human cells in GLP genotoxicity assays. In 1985, the company expanded research activities into the area of xenobiotic metabolism by developing cytochrome P450 cDNA-expression approaches. This led to the first commercial offering of cDNA-expressed human cytochrome P450 enzymes in 1990. Since that time, the range of Gentest offerings has increased dramatically, from recombinant systems to in vivo-like systems like primary hepatocytes. Now, as part of Corning Life Sciences, the Gentest offerings continue to grow, helping you stay on the leading edge of drug discovery and development.

Our scientists are internationally recognized as leaders and innovators in cytochrome P450 cDNA-expression, in vitro xenobiotic metabolism, and drug transporter techniques. Our demonstrated commitment to research has been rewarded by the receipt of several competitive NIH grants. The results and applications of our research are reported in peer reviewed journals and at international symposia by our scientists, colleagues, and customers interested in xenobiotic metabolism.

ADME/Tox Reagents


Advancing Real-world Studies

How to Buy

Purchasing Options

What’s New

Featured Products, Promotions, and More

Corning® HepatoCells

Corning® HepatoCells

Robust. Consistent. Convenient.

Corning HepatoCells are single-use, cryopreserved cells that are an excellent alternative model to primary human hepatocytes.

Corning HepatoCells deliver:

  • Robust activity induction response for major CYP enzymes
  • ≥10 fold induction for CYP3A4 and 1A2
  • Consistent performance
  • Low lot-to-lot variation
  • High cell purity (>99% hepatocyte-like cells)
  • ≥8 x 106 cells per vial
Learn More

Evaluation of Calibration Curve-based Approaches

Evaluation of Calibration Curve-based Approaches

Use Corning Gentest Human CryoHepatocytes to evaluate calibration curve-based approaches.

In a study conducted by Zhang et al, researchers were able to use Corning Gentest Human CryoHepatocytes to assess the amount of P450 induction in the liver by analyzing the concentration response curves of CYP3A4 mRNA in vitro, and established a predictive relationship between the chance in AUC in humans and parameters from CYP3A4 mRNA activity in vivo.

This research supports the use of calibration curve models and human hepatocytes to predict CYP3A4 induction potential in human patients, which can pave the way for clinical trials of potential new...

Learn More

New Corning Supersomes Ultra Human Aldehyde Oxidase

New Corning Supersomes Ultra Human Aldehyde Oxidase

A stable and reliable in vitro tool for the study of AO-mediated metabolism

Corning Supersomes Ultra Human Aldehyde Oxidase is a recombinant human AO enzyme that utlizes a mammalian cell-based expression system to address the issues associated with current market products, like recombinant AO expressed in bacteria.

Learn More

Featured Resources

TransportoCells FAQs

With the introduction of the solute carrier (SLC) over-expressing Corning TransportoCells, we have expanded our TransportoCells offering to conduct screening and use a step-wise approach for drug-drug interaction assays.

Questions? Download this FAQ on our new line of cryopreserved SLC transporter cells, or contact us.

Read More

Webinar: A Novel “Thaw and Go” Cell-based Model to Study SLC Transporters

See how our recently introduced TransportoCells products support in vitro assessment of drug interaction with SLC transporters. This new model provides a convenient “thaw and go” cell-based model with robust activity and consistent performance.

Watch Now

Gain Exclusive Access to Select Peer Reviewed Articles and Original Research from SLAS Discovery 2017

Through an SLAS and Corning Life Sciences partnership, we are pleased to offer exclusive access to 5 of the reports from the June 2017 issue of SLAS Discovery which showcases 3D cell culture as a rapidly emerging approach to cellular science and drug discovery.